Wendell David Associates Inc. Has $32.16 Million Holdings in Eli Lilly and Company $LLY

Wendell David Associates Inc. boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 1.2% during the third quarter, HoldingsChannel.com reports. The fund owned 42,149 shares of the company’s stock after purchasing an additional 494 shares during the period. Eli Lilly and Company accounts for 3.2% of Wendell David Associates Inc.’s portfolio, making the stock its 7th largest holding. Wendell David Associates Inc.’s holdings in Eli Lilly and Company were worth $32,160,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Vanguard Group Inc. lifted its position in shares of Eli Lilly and Company by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after buying an additional 1,183,038 shares during the period. Laurel Wealth Advisors LLC grew its position in Eli Lilly and Company by 78,621.2% in the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after acquiring an additional 11,537,661 shares during the period. Norges Bank acquired a new position in Eli Lilly and Company during the second quarter worth $8,827,714,000. Jennison Associates LLC lifted its holdings in shares of Eli Lilly and Company by 4.3% during the second quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock valued at $4,246,596,000 after acquiring an additional 226,620 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Eli Lilly and Company by 2.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 5,359,653 shares of the company’s stock valued at $4,178,010,000 after purchasing an additional 103,119 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY stock opened at $1,087.63 on Friday. The company has a 50 day moving average price of $1,056.39 and a 200 day moving average price of $878.04. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The stock has a market capitalization of $1.03 trillion, a PE ratio of 53.21, a price-to-earnings-growth ratio of 0.81 and a beta of 0.35.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same period last year, the firm earned $1.18 EPS. The business’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, February 13th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on LLY. BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a research report on Wednesday, January 14th. Scotiabank started coverage on shares of Eli Lilly and Company in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $1,165.00 price objective on the stock. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. The Goldman Sachs Group increased their price target on Eli Lilly and Company from $951.00 to $1,145.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Finally, National Bankshares set a $1,286.00 price target on Eli Lilly and Company in a report on Monday, December 1st. Four investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $1,174.61.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA granted Breakthrough Therapy designation for Lilly’s ovarian cancer candidate (sofetabart/mipitecan), improving the odds of faster development and a premium approval pathway for a novel oncology asset. Lilly receives FDA’s breakthrough therapy designation for ovarian cancer drug
• Positive Sentiment: Lilly launched a Phase 3b dosing study for retatrutide (obesity candidate), a near-term program de‑risk step that could support label expansion and broaden commercial use if results are favorable. Eli Lilly Advances Retatrutide With New Phase 3b Obesity Dosing Study
• Positive Sentiment: Data/real‑world studies continue to support obesity and metabolic franchises: SURMOUNT‑REAL UK (tirzepatide real‑world) updates and a retatrutide osteoarthritis signal suggest incremental clinical and commercial benefits beyond weight loss. These help underpin revenue upside for GLP/GIP drugs. Lilly’s SURMOUNT-REAL UK Trial: Real-World Test of Tirzepatide’s Obesity Upside
• Positive Sentiment: Lilly expanded its oncology imaging footprint with a new Phase 1 PET tracer study, signaling diversification into diagnostics/precision oncology that can boost long‑term margins and pipeline value. Eli Lilly Expands Oncology Imaging Footprint With New Phase 1 PET Tracer Study
• Positive Sentiment: Executives at the JPMorgan Healthcare Conference reiterated that the obesity market will evolve to include more pill options, combos and better access — a structural message that supports multi‑year demand growth for Lilly’s metabolic portfolio. What obesity drugmakers see next in the market: More pills, easier access and drug combinations
• Neutral Sentiment: Lilly confirmed its fourth‑quarter 2025 earnings release and conference call for Feb. 4 — a scheduled event that will likely drive near‑term volatility as investors re‑assess guidance and sales cadence. Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
• Neutral Sentiment: Organizational update: Lilly appointed Pranav Shroff as director of marketing — a routine personnel move with limited near‑term financial impact but relevant for commercial execution. Eli Lilly appoints Pranav Shroff as director of marketing
• Negative Sentiment: Competition risk in key international markets: Sun Pharma won approval for a Wegovy generic in India, intensifying price and market‑share pressure in a top growth region and foreshadowing similar generic/biologic competition scenarios. Eli Lilly, Novo Nordisk Set for Fierce Battle in India’s Obesity Drug Market as Sun Pharma Wins Wegovy Generic Nod
• Negative Sentiment: Legal/political overhang: coverage cites a lawsuit and public scrutiny over insulin pricing that can bring reputational and financial risk if litigation expands or results in penalties. Rokita Discusses Lawsuit Against Eli Lilly & Insulin Prices

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.